Ftse Mib
33.245,73
0,18%
DAX
18.300,06
0,52%
S&P 500
5.482,87
0,09%
NASDAQ
17.858,68
0,30%
Bitcoin
61.610,28
0,00%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Nkarta Inc (NKTX) Nkarta Inc (NKTX) Notizie

NKTX

Nkarta (NKTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NKTX
DataOraFonteTitoloSimboloCompagnia
27/06/202412:00GlobeNewswire Inc.Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune IndicationsNASDAQ:NKTXNkarta Inc
14/06/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTXNkarta Inc
14/06/202422:04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NKTXNkarta Inc
13/06/202422:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTXNkarta Inc
13/06/202422:01GlobeNewswire Inc.Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of DirectorsNASDAQ:NKTXNkarta Inc
09/05/202422:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NKTXNkarta Inc
09/05/202422:01GlobeNewswire Inc.Nkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:NKTXNkarta Inc
03/04/202422:02GlobeNewswire Inc.Nkarta to Participate in Upcoming Investor ConferencesNASDAQ:NKTXNkarta Inc
25/03/202411:30GlobeNewswire Inc.Nkarta Announces Pricing of $240 Million Underwritten OfferingNASDAQ:NKTXNkarta Inc
21/03/202421:01GlobeNewswire Inc.Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:NKTXNkarta Inc
01/03/202422:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTXNkarta Inc
09/02/202412:38Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NKTXNkarta Inc
03/01/202422:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NKTXNkarta Inc
10/12/202302:31GlobeNewswire Inc.Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & ExpositionNASDAQ:NKTXNkarta Inc
13/11/202314:25Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTXNkarta Inc
09/11/202322:02GlobeNewswire Inc.Nkarta Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:NKTXNkarta Inc
07/11/202314:02GlobeNewswire Inc.Nkarta to Participate at Upcoming Investor ConferencesNASDAQ:NKTXNkarta Inc
27/10/202322:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NKTXNkarta Inc
17/10/202318:00Dow Jones NewsNkarta's Stock Climbs 28% After FDA Approves Drug ApplicationNASDAQ:NKTXNkarta Inc
17/10/202317:47PR Newswire (US)Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus NephritisNASDAQ:NKTXNkarta Inc
17/10/202313:01GlobeNewswire Inc.Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus NephritisNASDAQ:NKTXNkarta Inc
16/10/202322:01GlobeNewswire Inc.Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost MeasuresNASDAQ:NKTXNkarta Inc
10/08/202313:01GlobeNewswire Inc.Nkarta Reports Second Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:NKTXNkarta Inc
03/08/202314:02GlobeNewswire Inc.Nkarta to Participate at Upcoming Investor ConferenceNASDAQ:NKTXNkarta Inc
05/07/202322:02GlobeNewswire Inc.Nkarta Appoints Alyssa Levin Chief Financial and Business OfficerNASDAQ:NKTXNkarta Inc
27/06/202313:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NKTXNkarta Inc
27/06/202313:01GlobeNewswire Inc.Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid LeukemiaNASDAQ:NKTXNkarta Inc
26/06/202322:01GlobeNewswire Inc.Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy ProgramNASDAQ:NKTXNkarta Inc
22/06/202322:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NKTXNkarta Inc
10/06/202316:47GlobeNewswire Inc.Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant LymphomaNASDAQ:NKTXNkarta Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NKTX

La tua Cronologia

TG
BS50
Inotiv
LSE
T3MP
Jpm Cl Ch S Etf
TG
NYT
N Y Times Cl A Dl 10
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network